GENEURO overview

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has renewed the provisional debt-restructuring moratorium granted to the Company in September 2024. The moratorium has been extended for an additional four months, until May 27, 2025, under the continued supervision of a court-appointed commissary. Debt-Restructuring Moratorium...

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as amyotrophic lateral sclerosis (ALS), today announced that groundbreaking findings on a potential precision medicine strategy for ALS with GeNeuro’s GNK-301 were presented at the 35th International Symposium on ALS/MND, taking place in Montreal, Canada, from December 6-8, 2024. The presentation...

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today reported on its 2023 second quarter cash position. 2023 Second-quarter financial information At 30 June 2023, GeNeuro had €8.0 million in cash. The available cash resources...

Regulatory News: Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont, as of 30 June 2023, the following assets appeared on the liquidity account: - Number of shares: 109,605 - Cash balance of the liquidity account: € 60,181.41 During the second half of 2022, the following shares were traded: PURCHASES 89,591 shares € 186,805.39 667 transactions SALES 91,658 shares € 196,627.82 555 transactions As a reminder, as of December 31, 2022, the following...

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of June 14, 2023. These included among others: Approval of the annual...

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), informs its shareholders that the 2023 Annual General Meeting will be held on Wednesday June 14, 2023 at 3.00 pm at its head office, 3, chemin du Pré-Fleuri, 1228 Plan-les-Ouates,...